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ABSTRACT         ARTICLE INFO______________________________________________________________     ______________________
Objectives: To compare the concordance of prostate cancer (PCa) laterality between 
the extended transperineal (TP) or transrectal (TR) prostate biopsy (BP) and radical 
prostatectomy (RP) specimens. To identify predictors of laterality agreement between 
BP and RP.
Materials and Methods: Data from 533 consecutive patients with PCa (278 TP and 255 
TR-diagnosed) treated with RP were analyzed. A 12-core technique was used for both 
TP and TR biopsies. Additional cores were obtained when necessary.
Results: Overall, the percentage of agreement of PCa laterality between BP and RP was 
60% (K = 0.27, p < 0.001). However, the RP confirmation of unilaterality at BP was 
obtained in just 33% of the cases. Considering the concordance on bilaterality as the 
“target” of our analysis, the sensitivity and specificity were 54.3% and 98.2%, respec-
tively, with TP and 47.5% and 92.5%, respectively with TR. Focusing on patients with 
unilaterality at biopsy, none of the evaluated preoperative variables (biopsy technique, 
age, total positive biopsy cores, PSA, prostate volume, Gleason score on biopsy) were 
able to predict RP bilaterality in the multivariate analyses.
Conclusions: Most of the patients with unilateral involvement at BP harbored bilateral 
PCa after RP. TR and TP biopsy showed no difference in their capacity to predict the 
concordance of tumor laterality at RP. None of the preoperative evaluated variables 
can predict the tumor laterality at RP. Using BP unilaterality to include patients in focal 
therapy (FT) protocols may hinder the oncologic efficacy of FT.
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INTRODUCTION
Recent pathologic studies from contemporary 
radical prostatectomy (RP) series have cited frequen-
cies of unifocal prostate cancer (PCa) ranging from 
10% to 44% and unilateral PCa ranging from 10% 
to 40% (1). In this context, focal therapy (both focal 
ablation and hemiablation) has progressively gained 
interest as a new method to control clinically locali-
zed PCa and has been defined as ‘a type of treatment 
that aims to eradicate known cancer within the pros-
tate and, at the same time, spare uninvolved prosta-
tic tissue, with the aim of preserving genitourinary 
function’ (2). Consequently, the accurate preoperative 
assessment of PCa is crucial and the exact spatial lo-
cation of the tumor is essential to deliver treatment.
 Transrectal ultrasound (TRUS)-guided biop-
sy of the prostate, performed through the transrectal 
(TR) or the transperineal (TP) approach is the current 
standard for the diagnosis of PCa and to define the 
localization of the disease. Several studies have inves-
tigated the degree of concordance in tumor laterality 
between prostate biopsy (BP) and RP (3-11) and its 
implication for focal therapy (3,4,6,8-11). However, 
in the majority of these studies the BP was performed 
through the transrectal approach; no data have been 
published on the transperineal approach, while the 
use of the perineal template has been recently descri-
bed, although the procedure is more invasive and has 
health-care resource implications (2,12,13). Multipa-
rametric MRI is receiving a great interest in the last 
years having the performance characteristics required 
to localize significant areas of prostate cancer, but the 
routine use of this technique can not be proposed for 
clinical (expertise of the radiologist) and health-care 
(cost and diffusion of MRI) implications (12).
 The aim of the current study was to compa-
re the concordance in the tumor laterality between 
the contemporary extended pattern prostate biopsy 
performed via a transperineal (TP) or transrectal (TR) 
approach and RP specimens in patients with PCa. Se-
condarily, we sought to identify predictors of latera-
lity agreement between the BP and RP.
MATERIALS AND METHODS
 Data from 533 consecutive patients with 
PCa diagnosed after an extended biopsy (278 via 
TP approach and 255 via TR approach) who un-
derwent RP were retrospectively analyzed. Seven 
different urology departments participated in the 
study. Three of these departments performed the 
TR biopsies (Denver, CO, USA; Rome, Italy; Tera-
mo, Italy), and the others performed the TP biopsies 
(Rome; Milan; Turin; Modena, Italy).
 TRUS guidance was used in all cases. The 
biopsy procedure was performed with an 18G 
biopsy needle in both TR and TP cases under local 
anesthesia. A 12-core technique was used in the TP 
biopsies (6 cores per lobe), covering the peripheral 
zone of both lobes from the lateral to the parame-
dian area and from the base to the apex. A 12-core 
technique was also followed for the TR biopsies, 
using the same scheme (two cores from the lateral 
peripheral zone, two from the paramedian-lateral 
zone and two from the paramedian apical and ba-
sal zone per lobe).
 For prostate volumes > 50 mL, two more 
peripheral cores (one from the lateral zone and one 
from the paramedian-lateral) were added. Additio-
nal cores from the anterior part or from the transi-
tion zone of the prostate were taken, depending on 
the clinical and ultrasound characteristics.
 RP was performed according to the surgical 
principles of each center. Each center had a dedica-
ted uropathologist examining the specimens (both 
of BP and RP). At all the participating centers, RP 
specimens were en-bloc formalin fixed and inked 
to delineate the surgical margins; a step-sectioned 
transversally at 2-4mm intervals technique was 
used to examine the specimen; an apical shaved-
-section, 2-4mm thick, was truncated perpendicu-
lar to the prostatic urethra and sub-sequentially 
sectioned as slices parallel to the prostatic urethra. 
Bladder neck was examined sampling portions of 
tissue at the junction of the prostatic capsule and 
bladder neck or by sampling the most proximal 
portion of the submitted specimen corresponding 
to the anatomical bladder neck. The 2002-TNM 
classification was used.
 The pathologic evaluation of the BP cores 
reported the ratio of total positive cores/total cores, 
laterality and the Gleason sum and score. The pa-
thologic evaluation of the RP specimens reported 
the laterality, Gleason sum and score, pathologic 
stage and margin status.
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Statistical analysis
The comparison of the patients’ baseline cha-
racteristics between the TR and TP groups was per-
formed in agreement with the statistical distribution 
of the variables (chi squared for nominal variables, 
Mann-Whitney for ordinal variables, t-test after log-
-transformation for interval scales such as PSA and 
prostate volume).
The concordance between the tumor laterali-
ty as assessed by BP and by RP was measured using 
the typical diagnostic indexes: sensitivity, specificity 
and accuracy. The chi-squared test was used to com-
pare the diagnostic performance of the two groups 
(TR and TP).
A multiple logistic-regression with bilatera-
lity at RP as the binary dependent variable and the 
biopsy approach (TP vs. TR), age, total positive spe-
cimens, PSA, Gleason score on biopsy and prostate 
volume as the independent categorical or continuous 
covariates was performed on cases with unilaterality 
at biopsy. The interactions between group-total po-
sitive specimens, group-prostate volume and group-
-pathological stage were also analyzed.
RESULTS
The demographic and baseline characteris-
tics are summarized in Table-1. As shown, the two 
groups of patients did not differ in terms of age, 
PSA levels, total biopsy cores, biopsy total Gleason 
score or prostate volume.
Overall, the percentage of correct classifica-
tions of the tumor laterality by biopsy with respect 
to prostatectomy was 60%. The Kappa measure of 
agreement was equal to 0.27. This value was statis-
tically significant (p < 0.001, thus rejecting the null 
hypothesis of lack of agreement). Specifically, we 
found that the overall prostatectomy confirmation 
of unilaterality at biopsy occurred only in 103 out 
of 311 cases (33%). Thus, the total agreement of 60% 
and the significant Kappa measurement were prima-
rily due to the cases classified as bilateral by biopsy 
and confirmed to be bilateral after RP (217/222 = 
97.7%). Considering the concordance of bilaterality 
(between the BP and RP) as the “target” of our analy-
sis, the overall biopsy sensitivity was low (51.1%), 
while the specificity was quite high (95.4%). When 
the BP suggested bilaterality, this was almost always 
true, while the BP indication of unilaterality was 
confirmed at RP in only 1 out of 3 cases.
We observed similar patterns when compa-
ring TP and TR. The percentage of correct concor-
dance in laterality was 62.9% (Kappa = 0.31, p < 
0.001) with TP and 56.9% (Kappa = 0.23, p < 0.001) 
with TR. The sensitivity and specificity with respect 
to bilaterality were 54.3% and 98.2%, respectively, 
with TP and 47.5% and 92.5%, respectively, with TR 
(Table-2). Even if TP showed slightly higher diag-
nostic performance, TP was not significantly better 
than TR in terms of sensitivity (p = 0.165), specifici-
ty (p = 0.157) and accuracy (p = 0.152).
The occurrence of a concordance between 
biopsy and prostatectomy was not dependent on the 
number of total BP cores (OR = 0.99, p = 0.717).
Focusing our analysis on cases classified as 
unilateral at biopsy, we sought to identify potential 
predictors of misclassification. Overall, none of the 
evaluated preoperative variables (biopsy technique, 
age, total positive biopsy cores, PSA, prostate volu-
me, Gleason score on biopsy) was able to predict the 
bilaterality of the final pathology on the multiva-
riate analyses (Table-3). Moreover, age, total positi-
ve biopsy cores, PSA, prostate volume and Gleason 
score on biopsy were not independent predictors 
of bilateral PCa within the TP and TR groups when 
analyzed separately.
DISCUSSION
 In recent years, due to the stage migra-
tion of PCa, there has been an increased interest 
in alternative strategies that offer the possibility 
of delaying, obviating or minimizing the impact 
of radical treatments (such as RP or radiotherapy), 
while maintaining the same oncologic long-term 
results. One such strategy is active surveillance 
with selective delayed intervention. Despite the 
advantages (avoiding overtreatment and compli-
cations in patients with low-risk PCa) and disad-
vantages (risk of progression and psychological 
and healthcare burdens) that have recently been 
addressed, definitive results from ongoing rando-
mized clinical trials are required to assess whether 
active surveillance should be routinely implemen-
ted in clinical practice (14).
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Table 1 - Baseline characteristics of the two groups (TP and TR) of patients.
TP (n = 278) TR (n = 255)
Mean SD 95% 
CI inf
95% CI 
sup
Mean SD 95% CI 
inf
95% CI 
sup
t-test(df), p-value
Age 64.6 5.8 63.9 65.3 64.0 6.2 63.2 64.7 1.192, p = 0.234
Total PSA 
(ng/ml)*
8.6 5.3 8.0 9.3 8.6 4.1 8.1 9.1 0.184, p = 0.854
Total biopsy 
cores
12.6 5.3 11.9 13.2 12.2 3.5 11.7 12.9 1.524, p = 0.342
Prostate 
volume 
(mL)*
38.9 29.7 35.3 42.4 42.3 16.7 40.3 44.5 1.738, p = 0.084
Biopsy Total 
Gleason 
score
6.6 0.9 6.5 6.7 6.4 0.7 6.3 6.5 1.826, p = 0.068
RP Total 
Gleason 
score
6.9 1.0 6.8 7.1 6.7 0.9 6.6 6.8 2.590, p = 0.010
pT stage
T2: n = 329 
(61.7%)
183 (65.9%) 146 (57.3%)
T3: n = 193 
(36.2%)
93 (33.3%) 100 (39.2%) Chi-Square (2) = 7.82, p = 0.020
T4: n = 11 
(2.1%)
2 (0.7%) 9 (3.5%)
Table 2 - Agreement between biopsy and prostatectomy in terms of tumor laterality.
Pathologic evaluation Prostatectomy (n=533)
PCa laterality Unilateral (n)
(% concordance)
Bilateral (n)
(% concordance)
TP (n = 278) Unilateral (n = 156) 54 (34.6) 102 (65.4)
Bilateral (n = 122) 1 (0.8) 121 (99.2)
TR (n = 255) Unilateral (n = 155) 49 (31.6) 106 (68.4)
Bilateral (n = 100) 4 (4) 96 (96)
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 Focal treatment may be an acceptable al-
ternative for low-risk PCa, representing a compro-
mise between the ambiguity of surveillance and the 
potential reduction of the quality of life of a radical 
treatment; aiming to destroy only the areas of PCa, 
focal therapy (FT) could deliver cancer control whi-
le simultaneously avoiding damage to the surroun-
ding structures (15). This may reduce incontinence, 
impotence, and rectal toxicity.
 Whether current hypotheses regarding the 
efficacy of FT suggest that it may be effective so long 
as it treats the “index lesion”, even if other lesions 
remain untreated in the gland, the optimal patient 
selection criteria for FT are not known and are there-
fore not standardized. Ongoing FT trials for PCa in-
clude the laterality, Gleason score and tumor volume 
as criteria for patient selection (1,12,16). The role of 
ultrasound and multiparametric MRI to define the 
exact disease localization is still debatable (12).
 Currently, TRUS-guided transrectal BP re-
mains the widespread approach to evaluate patient 
suitability for FT protocols in terms of tumor to-
pography, volume and grading. The accuracy of 
transrectal BP for predicting PCa laterality has been 
widely evaluated (3-9,11). All these studies but one 
(4) agree that almost two thirds of the patients with 
unilateral PCa at BP harbor bilateral PCa at RP and 
consequently BP is considered as inadequate for the 
purposes of candidate selection for FT.
 Only Polaschik et al. (4) suggested that BP 
unilaterality may be used to select men with low- 
to low-moderate-risk PCa for hemiablation FT. In 
their study, although less than one third of the pa-
tients had confirmed unilateral disease at the final 
pathological evaluation, the strongest predictor of 
pathologic unilaterality was prostate biopsy uni-
laterality (odds ratio [OR] = 3.88; 95% confidence 
interval [CI], 2.14-7.05; P < 0.0005).
 Furthermore, in these studies, none of the 
biopsy or clinical features, including the PSA, PSA 
ratio, clinical stage, gland volume, number of posi-
tive biopsy cores, high grade prostatic intraepithelial 
neoplasm, Gleason score, perineural invasion, percen-
tage of positive cores) could clearly and independen-
tly predict the presence of unilateral PCa in univa-
riate and multivariate logistic regression models.
 Increasing the number of BP cores is not tra-
duced in improving the accuracy of TRUS biopsy in 
predicting laterality. Abdollah et al (8) conducted a 
retrospective study on 203 patients who underwent 
an initial TRUS prostate saturation biopsy (24 cores) 
followed by RP. They concluded that initial satura-
tion BP is not sufficiently accurate as a method of 
predicting tumor laterality in RP specimens and that 
the use of saturation biopsy to guide hemi-ablation 
therapy of PCa may lead to mistreatment in a con-
siderable proportion of patients. Again, none of the 
routinely available clinical and pathological charac-
teristics appeared to improve the ability of unilateral 
PCa on biopsy to predict unilateral PCa in the RP 
specimen. The same conclusions were also reached 
by Falzarano et al (9) in a study based on 72 patients 
Table 3 - Multivariate analysis.
Odds Ratio 95% C.I.for OR p-value
Lower Upper
TR vs. TP 1.33 0.59 3.04 0.492
Age (years) 1.02 0.96 1.08 0.517
Total positive biopsy cores (n) 1.05 0.96 1.16 0.273
Total PSA (log) 1.01 0.58 1.78 0.964
Prostate volume (log) 1.04 0.47 2.29 0.926
Biopsy Gleason score 7 vs. <=6 0.63 0.30 1.32 0.219
Biopsy Gleason score >7 vs. <=6 0.82 0.19 3.61 0.797
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who underwent RP after saturation biopsy. Only 4 
of 39 patients (10%) with a unilateral positive TRUS 
saturation biopsy had unilateral cancer at the final 
pathological evaluation. Our study confirmed the 
poor role of extended TRUS biopsy to predict PCa 
laterality at final pathology, with a concordance rate 
of 31.6% for unilateral disease between BP and RP. 
The overall statistical significance of the Kappa me-
asurement of agreement that we obtained was rather 
reached due to the large sample size because a value 
of 0.27 conventionally indicates low agreement (17).
Is the extended TP biopsy more accurate for 
mapping PCa?
 To our knowledge, only an abstract by Hoshi 
et al (18) prospectively evaluated 147 consecutive 
men who subsequently underwent RP. The PPV of 
transperineal saturation BP (the probability that the 
tumor is unilateral on the final pathological exam 
when it was unilateral on preoperative biopsy) was 
only 30% and consequently this approach was not 
sufficiently accurate to detect unilateral PCa and it 
should not be used to decide which patients should 
be offered FT. However, a full-text manuscript did 
not follow this abstract.
 Template transperineal prostate mapping 
biopsies might provide more exact information 
about the spatial tumor distribution of PCa and 
might accurately identify unilateral cancer for the 
purpose of FT (13,19,20). When used with a 5mm 
sampling frame, this approach can rule in and rule 
out PCa foci of 0.5cc and 0.2cc volumes, with 90% 
certainty (19). There exists unanimous agreement 
that the current gold standard for characterizing 
men who are considering FT is transperineal BP 
using a template-guided approach, although it is 
not yet widely available and imposes a high bur-
den on healthcare services because of its require-
ment for anesthesia, pathology processing and slo-
wer reporting time (2). Moreover, correlation with 
whole-mount pathological specimens is necessary 
to fully analyze the accuracy of this technique, but 
to date, no study is available.
 Our study did not demonstrate any signifi-
cant advantage of the transperineal approach over 
the TR in the prediction of the laterality concordance 
of cancer. Even if TP showed slightly higher diag-
nostic performance, TP was not significantly better 
than TR in terms of sensitivity, specificity and ac-
curacy. When unilateral cancer was diagnosed after 
transperineal biopsy, the unilaterality was confirmed 
in only 34.6% of the patients, suggesting that, as 
with the transrectal approach, two thirds of the pa-
tients had bilateral cancer that was only detected at 
final pathology.
 Finally, none of the evaluated preoperative 
variables (biopsy technique, age, total positive biop-
sy cores, PSA, prostate volume and Gleason score on 
biopsy) were able to predict bilaterality at the final 
pathology in the multivariate analyses. Moreover, 
age, total positive biopsy cores, PSA, prostate volu-
me and Gleason score on biopsy were not indepen-
dent predictors of bilateral PCa within the TP and TR 
groups when analyzed separately.
 The present study is the first to report the 
accuracy of TP extended biopsy in predicting the 
laterality of PCa, and it is the first to compare TR 
versus TP in the same setting, with a standardized 
biopsy scheme. The absence of data on the clinical 
stage and the pathologic tumor volume as well as 
the absence of comparison on the complication rates 
and costs of the two bioptic approaches are the main 
shortcomings of our study.
CONCLUSIONS
 TRUS-guided biopsy is not accurate for 
predicting PCa laterality when compared to the RP 
pathology result. The majority of patients with uni-
lateral involvement at biopsy harbor bilateral PCa; 
the transperineal approach does not show any ad-
vantages over the transrectal in the capacity to pre-
dict the concordance of tumor laterality at radical 
prostatectomy. None of the preoperative evaluated 
variables can predict the final laterality. Thus, using 
unilaterality as a parameter for treating patients with 
FT may lead to mistreatment. Future research should 
aim to improve imaging techniques (such as multi-
parametric MRI) to obtain an accurate map of the 
prostate and understanding the biological implica-
tions of the different PCa foci for focusing treatment 
on the significant (“index”) lesions.
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